Treatment of severe steroid refractory acute graft versus host disease with Infliximab, a chimeric human/mouse anti-TNF-alpha antibody

被引：0
|
作者：
Kobbe, G
Schneider, P
Fenk, R
Rohr, U
Neumann, F
Aivado, M
Rong, A
Hünerlitürkoglu, A
Haas, R
机构：
来源：
BONE MARROW TRANSPLANTATION | 2001年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
  • [31] Plasma adiponectin levels in patients with infliximab treatment for steroid-refractory gastrointestinal acute graft-versus-host disease
    Murayama, Yoko
    Tsutsui, Shusaku
    Shinomura, Yasuhisa
    Hayashi, Norio
    GASTROENTEROLOGY, 2008, 134 (04) : A215 - A215
  • [32] Repeated infusions of anti-TNF-alpha chimeric antibody (cA2) maintain remission in refractory Crohn's disease
    DHaens, G
    Rutgeerts, P
    vanDeventer, SJH
    Present, DH
    Mayer, L
    Hanauer, SB
    Braakman, TAJ
    DeWoody, KL
    Schaible, TF
    Targan, SR
    GUT, 1997, 41 : A68 - A69
  • [33] Treatment of steroid refractory acute graft-versus-host disease (GHVD) by monoclonal antibody, ABX-CBL.
    Deeg, HJ
    Bolwell, BJ
    Long, G
    Blazar, BR
    Schuening, F
    Cunningham, J
    Rifkin, RM
    Briggs, AD
    Burt, R
    Abhyankar, S
    Havrilla, N
    BLOOD, 1999, 94 (10) : 667A - 667A
  • [34] Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
    Kobrinski, Daniel
    Rodriguez, Tulio E.
    Smith, Scott E.
    Tsai, Stephanie B.
    Al-Mansour, Zeina
    Parthasarathy, Mala
    Stiff, Patrick J.
    BLOOD, 2016, 128 (22)
  • [35] EFFICACY AND SAFETY OF INFLIXIMAB THERAPY IN THE SETTING OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
    Halahleh, Khalid
    Al Shurman, Jana
    Taqash, Ayat
    Ma'koseh, Mohammad
    Abu Khader, Ahmad
    Muradi, Isra
    Da'na, Waleed
    Rihani, Rawad
    BONE MARROW TRANSPLANTATION, 2024, 59 : 340 - 341
  • [36] Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease
    Yalniz, Fevzi E.
    Hefazi, Mehrdad
    McCullough, Kristen
    Litzow, Mark R.
    Hogan, William J.
    Wolf, Robert
    Alkhateeb, Hassan
    Kansagra, Ankit
    Damlaj, Moussab
    Patnaik, Mrinal M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (09) : 1478 - 1484
  • [37] Tocilizumab for steroid refractory acute graft-versus-host disease
    Roddy, Julianna V. F.
    Haverkos, Bradley M.
    McBride, Ali
    Leininger, Kathryn M.
    Jaglowski, Samantha
    Penza, Sam
    Klisovic, Rebecca
    Blum, William
    Vasu, Sumithira
    Hofmeister, Craig C.
    Benson, Don M.
    Andritsos, Leslie A.
    Devine, Steven M.
    Efebera, Yvonne A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 81 - 85
  • [38] Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract
    Ganetsky, Alex
    Frey, Noelle V.
    Hexner, Elizabeth O.
    Loren, Alison W.
    Gill, Saar I.
    Luger, Selina M.
    Mangan, James K.
    Martin, Mary Ellen
    Babushok, Daria V.
    Drobyski, William R.
    Smith, Jacqueline
    Timlin, Colleen
    Freyer, Craig W.
    Stadtmauer, Edward A.
    Porter, David L.
    BONE MARROW TRANSPLANTATION, 2019, 54 (02) : 212 - 217
  • [39] Pentostatin in steroid refractory acute graft versus host disease.
    Jacobsohn, D
    Margolis, J
    Anders, V
    Phelps, M
    Grever, M
    Vogelsang, G
    BLOOD, 2002, 100 (11) : 420A - 420A
  • [40] BORTEZOMIB FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (GVHD)
    Wagner, J. L.
    Mookajee, B.
    Filicko-O'Hara, J. E.
    Grosso, D. A.
    Flomenberg, N.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S370 - S370
12345